UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  02/25/2014
 
ImmunoCellular Therapeutics, Ltd.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-35560
 
Delaware
  
93-1301885
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
23622 Calabasas Road, Suite 300
Calabasas, California 91302
(Address of principal executive offices, including zip code)
 
(818) 264-2300
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 8.01.    Other Events
 
On February 25, 2014, ImmunoCellular Therapeutics, Ltd. issued a press release entitled, "ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union," a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference.
 
 
Item 9.01.    Financial Statements and Exhibits
 
99.1 Press Release, dated February 25, 2014, entitled, "ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union."
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
           
ImmunoCellular Therapeutics, Ltd.
 
 
Date: February 25, 2014
     
By:
 
/s/    Andrew Gengos

               
Andrew Gengos
               
President and Chief Executive Officer
 
 


 

EXHIBIT INDEX
 
Exhibit No.

  
Description

EX-99.1
  
PRESS RELEASE, DATED FEBRUARY 25, 2014
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more EOM Pharmaceutical (PK) Charts.
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more EOM Pharmaceutical (PK) Charts.